EAM
RGLS

Empery Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Empery Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-507,425
Closed -$1.6M – 82
2021
Q4 		$1.6M Buy
+507,425
New +$2.25M 3.34% 11

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Empery Asset Management's RGLS Position: Q1 2022 in Review

Empery Asset Management sold out of Regulus Therapeutics (RGLS) in Q1 2022, closing a stake of 507,425 shares — an estimated $1.6M sold.

Empery Asset Management first reported a position in RGLS in Q4 2021 and held it in 1 quarter. The position peaked at $1.6M in Q4 2021. 36 funds tracked by Wall St. Rank hold RGLS as of Q1 2022.

  • Empery Asset Management reported no remaining Regulus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Empery Asset Management sold 507,425 Regulus Therapeutics shares in Q1 2022, an estimated $1.6M.
  • Empery Asset Management first reported a position in Regulus Therapeutics in Q4 2021 and held it in 1 quarter.
  • Empery Asset Management's Regulus Therapeutics position peaked at $1.6M in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2022.

Based on Empery Asset Management's 13F filing for Q1 2022, filed 16 May 2022.